Swedish Orphan Biovitrum AB (SOBI.XSTO) Dividend Analysis
This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in company filings.
Does Swedish Orphan Biovitrum AB (SOBI.XSTO) pay a dividend?
Swedish Orphan Biovitrum AB (SOBI.XSTO) has never paid a dividend. The business does generate free cash flow of SEK 4.5 billion, so the absence of a dividend is a capital-allocation choice rather than an inability to pay. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Swedish Orphan Biovitrum AB (SOBI.XSTO) pay a dividend?+
No. Swedish Orphan Biovitrum AB (SOBI.XSTO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Swedish Orphan Biovitrum AB return cash to shareholders?+
It largely does not. Swedish Orphan Biovitrum AB pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Could Swedish Orphan Biovitrum AB afford to pay a dividend?+
On the numbers, yes. Swedish Orphan Biovitrum AB generated SEK 4.5 billion of free cash flow, which is about SEK 12.98 per share. If it paid out half of that, the dividend would be roughly SEK 6.49 per share, a yield of about 1.5% at the current price. That is an illustration of capacity, not a prediction: the company has given no indication it intends to pay one.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Swedish Orphan Biovitrum AB.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.